NCT06842199

Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Oral ICP-488 in Patients With Moderate to Severe Plaque Psoriasis

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 383 (estimated)
• Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the efficacy, safety, PK characteristics of ICP-488 in Chinese adults with moderate to severe plaque psoriasis.

Conditions

• Plaque Psoriasis Patients

Interventions

Type	Name	Description
DRUG	ICP-488 Tablets	Eligible patients will receive ICP-488 orally as per the protocol
DRUG	ICP-488 Placebo	Eligible patients will receive ICP-488 Placebo orally as per the protocol

Timeline

• Start date: 2025-03-20
• Primary completion: 2026-05-01
• Completion: 2027-02-01
• First posted: 2025-02-24
• Last updated: 2026-02-09

Locations

46 sites across 1 country: China